Delivery Order SPE2DB20D1110-SPE2DB25FK37H
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector pre-filled syringes valued at $1,716.22. This is a firm fixed price delivery order with an ultimate completion date of July 15, 2025, and represents a non-competitive set-aside award. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract, this delivery order is issued...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,678.14 for Xyosted 75 mg/0.5 mL auto-injector supplies on August 4, 2025, with completion targeted for August 5, 2025. This firm fixed-price, non-set-aside delivery order will be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,936.96 delivery order on July 23, 2025, for XYOSTED 75 mg/0.5 mL auto-injector units (0.5 mL). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 24, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's larger pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 11, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector units valued at $1,094.38 with a firm fixed price structure. This non-set-aside contract is classified as a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The ultimate completion date for this delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Xyosted 50 mg/0.5 ml auto-injector pre-filled pens valued at $1,653.41. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of September 23, 2025. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector units with a ceiling value of $1,346.07. This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order with performance to be completed by August 27, 2025, at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a $10,032.76 delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector supplies on September 12, 2025, with completion targeted for September 15, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement that extends through December 2026. The...
- The Defense Logistics Agency awarded a $1,752.22 delivery order to AmerisourceBergen Drug Corp for Xyosted 50 mg/0.5 mL auto-injectors on September 5, 2025, with completion scheduled for September 8, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract and will be performed at the contractor's Conshohocken, Pennsylvania facility. Xyosted is a testosterone replacement therapy medication delivered via auto-injector, reflecting the Defense...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,716.10 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injectors on August 5, 2025, with completion expected by August 6, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- This delivery order, awarded July 28, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides Xyosted 100 mg/0.5 mL auto-injector pharmaceutical supplies with a ceiling value of $1,092.55. The contract utilizes firm fixed pricing and is scheduled for completion by July 29, 2025. As a non-set-aside, competitively awarded delivery order, this award represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA. The place of...
- SPE2DB20D1110Indefinite Delivery Contract
- SPE2DB20D1110-SPE2DB25FK37HDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector medication with a contract ceiling value of $2,476.04. This firm fixed-price delivery order, which extends through August 29, 2025, represents a pediatric or adult testosterone replacement therapy product to support federal medical supply requirements. The contract was competitively awarded without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a primary pharmaceutical distributor for the Defense Logistics Agency's Medical Supply Chain, AmerisourceBergen supplies a comprehensive portfolio of medications and medical devices to support military healthcare systems, the Defense Health Agency, and other federal health programs globally. The company's extensive federal contracting portfolio demonstrates its established capability to fulfill competitive pharmaceutical procurement requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 8/28/25 |